These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27185478)

  • 1. Investigation of bacterial inactivation in apheresis platelets with 24 or 30 hours between inoculation and inactivation.
    Wagner SJ; Benjamin RJ; Hapip CA; Kaelber NS; Turgeon AM; Skripchenko A; Stassinopoulos A
    Vox Sang; 2016 Oct; 111(3):226-234. PubMed ID: 27185478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
    Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
    Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of riboflavin and ultraviolet light treatment against Klebsiella pneumoniae in whole blood-derived platelets: A pilot study.
    Alabdullatif M; Osman IE; Alrasheed M; Ramirez-Arcos S; Alyousef M; Althawadi S; Alhumiadan H
    Transfusion; 2021 May; 61(5):1562-1569. PubMed ID: 33687079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function.
    Knutson F; Alfonso R; Dupuis K; Mayaudon V; Lin L; Corash L; Högman CF
    Vox Sang; 2000; 78(4):209-16. PubMed ID: 10895093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function.
    Sandgren P; Diedrich B
    Vox Sang; 2015 May; 108(4):340-9. PubMed ID: 25557354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions.
    Arnason NA; Johannson F; Landrö R; Hardarsson B; Irsch J; Gudmundsson S; Rolfsson O; Sigurjonsson OE
    Transfusion; 2019 Dec; 59(12):3727-3735. PubMed ID: 31674051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of coagulation function in thawed apheresis plasma for photochemical treatment by amotosalen and UVA.
    de Valensart N; Rapaille A; Goossenaerts E; Sondag-Thull D; Deneys V
    Vox Sang; 2009 Apr; 96(3):213-8. PubMed ID: 19207170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
    Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
    Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Scansystem method for detection of bacterially contaminated platelets.
    Jacobs MR; Bajaksouzian S; Windau A; Palavecino EL; Yomtovian R
    Transfusion; 2005 Feb; 45(2):265-9. PubMed ID: 15660837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.
    Cid J
    Vox Sang; 2017 Oct; 112(7):607-613. PubMed ID: 28833219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage.
    Cancelas JA; Genthe JR; Stolla M; Rugg N; Bailey SL; Nestheide S; Shaz B; Mack S; Schroeder K; Anani W; Szczepiorkowski ZM; Dumont LJ; Yegneswaran S; Corash L; Mufti N; Benjamin RJ; Erickson AC
    Transfusion; 2022 Aug; 62(8):1619-1629. PubMed ID: 35808974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.
    Lin L; Dikeman R; Molini B; Lukehart SA; Lane R; Dupuis K; Metzel P; Corash L
    Transfusion; 2004 Oct; 44(10):1496-504. PubMed ID: 15383024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the inactivation capabilities of two commercially available platelet component pathogen inactivation systems: effectiveness at end of shelf life.
    McDonald CP; Bearne J; Aplin K; Sawicka D
    Vox Sang; 2021 Apr; 116(4):416-424. PubMed ID: 33616238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen.
    Cazenave JP; Aleil B; Wiesel ML; Laforêt M; Isola H
    Vox Sang; 2004 Apr; 86(3):201-2. PubMed ID: 15078258
    [No Abstract]   [Full Text] [Related]  

  • 15. Inactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination.
    Santa Maria F; Laughhunn A; Lanteri MC; Aubry M; Musso D; Stassinopoulos A
    Transfusion; 2017 Aug; 57(8):2016-2025. PubMed ID: 28671343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial contamination of platelets for transfusion: strategies for prevention.
    Levy JH; Neal MD; Herman JH
    Crit Care; 2018 Oct; 22(1):271. PubMed ID: 30367640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the BacT/Alert automated blood culture system for detecting bacteria and measuring their growth kinetics in leucodepleted and non-leucodepleted platelet concentrates.
    McDonald CP; Roy A; Lowe P; Robbins S; Hartley S; Barbara JA
    Vox Sang; 2001 Oct; 81(3):154-60. PubMed ID: 11703857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets.
    Schrezenmeier H; Walther-Wenke G; Müller TH; Weinauer F; Younis A; Holland-Letz T; Geis G; Asmus J; Bauerfeind U; Burkhart J; Deitenbeck R; Förstemann E; Gebauer W; Höchsmann B; Karakassopoulos A; Liebscher UM; Sänger W; Schmidt M; Schunter F; Sireis W; Seifried E
    Transfusion; 2007 Apr; 47(4):644-52. PubMed ID: 17381623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology.
    Girard YA; Santa Maria F; Lanteri MC
    Transfusion; 2020 Mar; 60(3):622-627. PubMed ID: 31957887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Intercept pathogen reduction treatment on extended cold storage of apheresis platelets.
    Agey A; Reddoch-Cardenas K; McIntosh C; Sharma U; Cantu C; Cap A; Bynum J
    Transfusion; 2021 Jan; 61(1):167-177. PubMed ID: 33295030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.